Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Seven pharmaceutical giants with a presence in New Jersey have announced billions in expansions. The timing is no surprise, health care analysts say.

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

Novo Nordisk accounts for 34% of the global diabetes ... qualities that it shares with the only two other global insulin players, Sanofi and Eli Lilly. However, we don't think Novo's cost ...

Novo Nordisk's CEO, who led its boom driven by obesity and diabetes medications only to see that success stall, is stepping ...

In a report released today, Benjamin Jackson CFA from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €120.00. The company’s sh ...

June 3, 2025 expert reaction to observational study on low calorie diets and depressive symptoms . An observational study published in BMJ Nutrition, Prevention & Health looks at ...

Access to diabetes care in lower-income countries still lags for children, despite efforts from insulin makers.

Skyline view of the City of London financial district from the viewpoint in Greenwich Park in London, United Kingdom. This is ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.